{"id":1854,"date":"2026-11-05T18:25:03","date_gmt":"2026-11-05T18:25:03","guid":{"rendered":"https:\/\/homelymd.com\/blogs\/?p=1854"},"modified":"2026-11-05T18:25:05","modified_gmt":"2026-11-05T18:25:05","slug":"interim-access-policy-telehealth-peptide-program","status":"publish","type":"post","link":"https:\/\/homelymd.com\/blogs\/interim-access-policy-telehealth-peptide-program\/","title":{"rendered":"FDA&#8217;s Interim Access Policy for Peptides: What It Means for Your Telehealth Peptide Program"},"content":{"rendered":"\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table of Contents<\/h2><nav><ul><li><a href=\"#key-takeaways\">Key takeaways\u00a0<\/a><\/li><li><a href=\"#what-the-policy-actually-is\">What the policy actually is\u00a0<\/a><ul><li><a href=\"#the-six-covered-peptides\">The six covered peptides\u00a0<\/a><\/li><\/ul><\/li><li><a href=\"#how-we-got-here-a-short-timeline\">How we got here: a short timeline\u00a0<\/a><\/li><li><a href=\"#the-10-conditions-your-503-a-pharmacy-peptides-compliance-checklist\">The 10 conditions: your 503A pharmacy peptides compliance checklist\u00a0<\/a><\/li><li><a href=\"#what-this-means-for-a-telehealth-peptide-program\">What this means for a telehealth peptide program\u00a0<\/a><\/li><li><a href=\"#state-law-still-matters-peptide-prescribing-and-telemedicine-compliance\">State law still matters: peptide prescribing and telemedicine compliance\u00a0<\/a><\/li><li><a href=\"#how-to-offer-peptides-through-telehealth-a-step-by-step-plan\">How to offer peptides through telehealth: a step-by-step plan\u00a0<\/a><\/li><li><a href=\"#where-a-white-label-telehealth-platform-fits\">Where a white-label telehealth platform fits\u00a0<\/a><\/li><li><a href=\"#ready-to-build-your-telehealth-peptide-program\">Ready to build your telehealth peptide program?\u00a0<\/a><ul><li><a href=\"#frequently-asked-questions\">Frequently asked questions\u00a0<\/a><ul><li><a href=\"#is-the-fd-as-interim-access-policy-for-peptides-a-law\">Is the FDA&#8217;s interim access policy for peptides a law?\u00a0<\/a><\/li><li><a href=\"#are-peptides-now-fda-approved-or-fully-legal-to-sell\">Are peptides now FDA-approved or fully legal to sell?\u00a0<\/a><\/li><li><a href=\"#which-peptides-does-the-policy-cover\">Which peptides does the policy cover?\u00a0<\/a><\/li><li><a href=\"#how-do-i-offer-peptides-through-telehealth\">How do I offer peptides through telehealth?\u00a0<\/a><\/li><li><a href=\"#do-i-need-a-503-a-compounding-pharmacy-partner\">Do I need a 503A compounding pharmacy partner?\u00a0<\/a><\/li><li><a href=\"#does-the-policy-cover-peptide-blends-or-stacks\">Does the policy cover peptide blends or stacks?\u00a0<\/a><\/li><li><a href=\"#how-do-i-start-a-telehealth-peptide-business\">How do I start a telehealth peptide business?\u00a0<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">For the last three years, building a <a href=\"https:\/\/homelymd.com\/blogs\/telehealth-peptide-therapy-online-care\/\"><strong>telehealth peptide program<\/strong><\/a> <strong><\/strong>meant operating in a gray zone. Many of the most requested peptides sat on the FDA&#8217;s &#8220;do not compound&#8221; list, and demand moved to gray-market &#8220;research use only&#8221; vials instead. On October 28, 2026, that changed. The federal government released an interim policy that gives licensed pharmacies a defined, conditional path to compound six peptides while formal rulemaking plays out.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If you are planning to <a href=\"https:\/\/homelymd.com\/blogs\/what-do-you-need-to-start-a-peptide-clinic\/\"><strong>start a telehealth peptide business<\/strong><\/a>, add peptides to an existing clinic, or <a href=\"https:\/\/homelymd.com\/brands\"><strong>launch a peptide brand<\/strong><\/a>, this policy matters. But it is narrower than the headlines suggest. This guide explains what it covers, what it does not, and how to build a compliant program on top of it.&nbsp;<\/p>\n\n\n\n<h2 id=\"key-takeaways\" class=\"wp-block-heading\"><strong>Key takeaways&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 HHS will not take enforcement action against state-licensed 503A pharmacies, federal facilities, or licensed physicians compounding <strong>six peptides<\/strong> (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) when <strong>all 10 conditions<\/strong> are met.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 It is <strong>not an FDA approval<\/strong>, it does not add the peptides to the 503A bulks list, and it is labeled a draft that does not bind HHS or the public.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 It covers <strong>503A pharmacies only<\/strong>, with a patient-specific prescription. Outsourcing facilities (503B) and research-use-only products are not covered.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>State law still applies.<\/strong> Medical and pharmacy boards are not bound by the federal policy. \u2022 Public comments are due <strong>November 13, 2026<\/strong>. The policy can be changed or withdrawn at HHS&#8217;s discretion.&nbsp;<\/p>\n\n\n\n<h2 id=\"what-the-policy-actually-is\" class=\"wp-block-heading\"><strong>What the policy actually is&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The document was first sent to the White House Office of Management and Budget on October 14 under the working title &#8220;Interim Access Policy for Compounding Using Certain Peptides.&#8221; It was released on October 28 and published in the Federal Register on October 30 as a draft, titled the Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It was issued by HHS, and HHS says its goals are to expand patient access and to steer people away from research-use-only peptides made by foreign manufacturers toward a more controlled, prescription-based alternative.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Enforcement discretion&#8221; is not legal authorization. It means the agency has said it does not intend to act against compounders who follow the stated conditions. The policy stays in effect until each peptide is addressed in a final rule on the 503A bulks list, which requires a proposed rule, public comment, and a final rule. That could take a long time, and HHS may amend the policy in the meantime.&nbsp;<\/p>\n\n\n\n<h3 id=\"the-six-covered-peptides\" class=\"wp-block-heading\"><strong>The six covered peptides&nbsp;<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Peptide&nbsp;<\/strong><\/td><td><strong>Form&nbsp;<\/strong><\/td><td><strong>Routes covered by the policy<\/strong><\/td><\/tr><tr><td>BPC-157&nbsp;<\/td><td>Acetate&nbsp;<\/td><td>Subcutaneous, intramuscular, oral, topical<\/td><\/tr><tr><td>Epitalon&nbsp;<\/td><td>Acetate&nbsp;<\/td><td>Subcutaneous or intramuscular, dispensed in intermittent courses<\/td><\/tr><tr><td>KPV&nbsp;<\/td><td>Acetate&nbsp;<\/td><td>Oral and topical<\/td><\/tr><tr><td>MOTS-c&nbsp;<\/td><td>Acetate&nbsp;<\/td><td>Subcutaneous or intramuscular<\/td><\/tr><tr><td>Semax&nbsp;<\/td><td>Free base&nbsp;<\/td><td>Intranasal<\/td><\/tr><tr><td>TB-500&nbsp;<\/td><td>Acetate&nbsp;<\/td><td>Subcutaneous or intramuscular<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Peptides such as CJC-1295, ipamorelin, AOD-9604, and emideltide are not in the policy&#8217;s appendix, so they get no protection from it. If your protocol relies on them, treat them as outside this policy and talk to your pharmacy and counsel.&nbsp;<\/p>\n\n\n\n<h2 id=\"how-we-got-here-a-short-timeline\" class=\"wp-block-heading\"><strong>How we got here: a short timeline&nbsp;<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Date&nbsp;<\/strong><\/td><td><strong>Event<\/strong><\/td><\/tr><tr><td>2023&nbsp;<\/td><td>FDA places roughly 19 peptides in Category 2 of its interim bulks policy (significant safety concerns), effectively blocking routine 503A compounding.<\/td><\/tr><tr><td>Apr 15, 2026&nbsp;<\/td><td>FDA moves to remove 12 peptides from Category 2 after nominations were withdrawn. Removal alone did not make them eligible for compounding.<\/td><\/tr><tr><td>Jul 23-24, 2026&nbsp;<\/td><td>FDA&#8217;s Pharmacy Compounding Advisory Committee votes to recommend six of seven peptides for the bulks list, over the objection of FDA&#8217;s own reviewers.<\/td><\/tr><tr><td>Oct 14, 2026&nbsp;<\/td><td>HHS and FDA send the interim access policy to the White House for review.<\/td><\/tr><tr><td>Oct 28-30, 2026&nbsp;<\/td><td>HHS releases the draft enforcement discretion policy; Federal Register publication follows on Oct 30.<\/td><\/tr><tr><td>Nov 13, 2026&nbsp;<\/td><td>Public comment deadline.<\/td><\/tr><tr><td>Feb 2027&nbsp;<\/td><td>The advisory committee is scheduled to review five more peptides: Cathelicidin, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"the-10-conditions-your-503-a-pharmacy-peptides-compliance-checklist\" class=\"wp-block-heading\"><strong>The 10 conditions: your 503A pharmacy peptides compliance checklist&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Enforcement discretion applies only when all ten circumstances are present. Think of this list as a due-diligence worksheet for your <a href=\"http:\/\/homelymd.com\/pharmacy-rx\"><strong>peptide compounding pharmacy partner<\/strong><\/a>, and as a set of standards your clinical team can audit against.<br><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>#&nbsp;<\/strong><\/td><td><strong>Condition&nbsp;<\/strong><\/td><td><strong>What it means for your program<\/strong><\/td><\/tr><tr><td>1&nbsp;<\/td><td>Only the six listed peptides&nbsp;<\/td><td>Build your formulary around the six. Anything else is outside the policy.<\/td><\/tr><tr><td>2&nbsp;<\/td><td>Correct identity and route&nbsp;<\/td><td>The peptide must match the listed identity and approved routes (for example, intranasal only for Semax).<\/td><\/tr><tr><td>3&nbsp;<\/td><td>Registered source and valid COA<\/td><td>Bulk substance comes from an FDA-registered facility with a valid certificate of analysis. Ask your pharmacy for documentation.<\/td><\/tr><tr><td>4&nbsp;<\/td><td>Original manufacturer&nbsp;disclosures<\/td><td>The original manufacturer is FDA-registered, follows cGMP, and its physical location is on the COA. Resellers and repackers must have validated the manufacturer.<\/td><\/tr><tr><td>5&nbsp;<\/td><td>Reporting&nbsp;<\/td><td>Serious adverse events and product quality issues go to FDA MedWatch and to the relevant states. Patient labeling explains how to report.<\/td><\/tr><tr><td>6&nbsp;<\/td><td>Label statement&nbsp;<\/td><td>Label reads: This is a compounded drug product. Not for resale.<\/td><\/tr><tr><td>7&nbsp;<\/td><td>Single active ingredient&nbsp;<\/td><td>No blends. Multi-peptide &#8220;stacks&#8221; in one product fall outside the policy.<\/td><\/tr><tr><td>8&nbsp;<\/td><td>Oral bioavailability proof&nbsp;<\/td><td>Oral forms need documentation that the formulation achieves adequate absorption in humans. This is a real hurdle for some pharmacies.<\/td><\/tr><tr><td>9&nbsp;<\/td><td>Delivery device&nbsp;<\/td><td>The only co-packaged device allowed is an FDA 510(k)-cleared syringe.<\/td><\/tr><tr><td>10&nbsp;<\/td><td>All other FD&amp;C Act&nbsp;requirements<\/td><td>Sanitary compounding and a valid patient-specific prescription are still required.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Several of these conditions mostly fall on the pharmacy (3, 4, 7, 8, 9), but your brand and prescribers share responsibility for the rest, especially adverse event handling, labeling, and prescribing practices.&nbsp;<\/p>\n\n\n\n<h2 id=\"what-this-means-for-a-telehealth-peptide-program\" class=\"wp-block-heading\"><strong>What this means for a telehealth peptide program&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. A defined, lower-risk lane for prescription peptide therapy&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Before October 28, <a href=\"https:\/\/homelymd.com\/white-label-telehealth-platform\"><strong>peptide telehealth<\/strong><\/a> <strong><\/strong>programs relied on informal assumptions about enforcement. Now there is a written federal framework. Observers generally describe the practical effect as de-risking compounding of these six peptides, as long as the pharmacy aligns with all ten conditions.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. It does not turn peptides into approved drugs&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The six peptides remain unapproved. Reviewers at FDA&#8217;s drug center recommended against adding every one of them to the bulks list, and the policy itself acknowledges that. Compounded products are also unlikely to be covered by insurance. Your patient materials, website, and ads should never say &#8220;FDA-approved,&#8221; &#8220;FDA-cleared,&#8221; or &#8220;now legal.&#8221; Describe them accurately: prescribed, compounded, patient-specific, and not FDA-approved.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. Peptides for weight loss: be precise<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br><a href=\"https:\/\/homelymd.com\/blogs\/glp-1-medications-weight-loss-online-telehealth\/\"><strong>Peptides for weight loss<\/strong><\/a> <strong><\/strong>is a high-volume search term, and it is where compliance mistakes happen. None of the six covered peptides is approved for weight loss. MOTS-c was nominated for obesity and osteoporosis, but FDA reviewers cited limited human evidence across these peptides. GLP-1 medications are peptide-based drugs too, but they are regulated separately and are not part of this policy. Keep weight-loss marketing tied to what your licensed clinicians can substantiate.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. Research-use-only is not a workaround&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The policy is designed to move demand away from research-use-only products. It extends no protection to peptides sold outside the pharmacy system, and FDA has already sent warning letters to online vendors. A legitimate program is prescription-only, through a licensed pharmacy.&nbsp;<\/p>\n\n\n\n<h2 id=\"state-law-still-matters-peptide-prescribing-and-telemedicine-compliance\" class=\"wp-block-heading\"><strong>State law still matters: peptide prescribing and telemedicine compliance&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The federal policy does not bind state boards of medicine or pharmacy. Telehealth does not erase state licensing and prescribing rules, and peptide prescribing sits under two layers of regulation: federal compounding rules and state law. Before you launch in any state, check:&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Provider licensure:<\/strong> the prescriber must be licensed where the patient is located. \u2022 <strong>Scope of practice:<\/strong> NP and PA prescribing authority, collaboration, and supervision rules vary by state.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Telehealth rules:<\/strong> whether the state permits evaluation, prescribing, and follow-up for compounded medications by telehealth.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Pharmacy licensure and shipping:<\/strong> some states require out-of-state pharmacies to register before shipping to residents, and the pharmacy must be licensed where required. \u2022 <strong>State compounding rules:<\/strong> some states add requirements beyond federal 503A conditions. California, for example, has codified a stricter standard in some areas.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Standard of care:<\/strong> state boards can act on prescribing that falls below the standard of care, including inadequate evaluation, consent, and monitoring.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Do not assume any state is &#8220;peptide friendly.&#8221; Verify the provider, pharmacy, compound, route, and state together.&nbsp;<\/p>\n\n\n\n<h2 id=\"how-to-offer-peptides-through-telehealth-a-step-by-step-plan\" class=\"wp-block-heading\"><strong>How to offer peptides through telehealth: a step-by-step plan&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Whether you are a founder, a clinic owner, or a <strong>med spa peptide program<\/strong> operator planning to <a href=\"https:\/\/homelymd.com\/blogs\/what-do-you-need-to-start-a-peptide-clinic\/\"><strong>start a peptide clinic<\/strong><\/a>, this sequence keeps you inside the policy&#8217;s guardrails.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. Pick your launch lane.<\/strong> Decide whether you are building a new brand, adding peptides to an existing practice, or launching through your audience. Start with the six covered peptides and the routes listed for each.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. Choose a 503A pharmacy partner and verify the 10 conditions in writing.<\/strong> Ask for COAs, original manufacturer registration and location, reporting procedures, labeling, single-API confirmation, and (for oral products) bioavailability documentation.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. Set your clinical protocol.<\/strong> Define intake, history review, contraindication screening, baseline labs, informed consent that explains the product is compounded and not FDA-approved, and a monitoring and follow-up schedule.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. Map your state footprint.<\/strong> Confirm provider licensure, scope of practice, telehealth rules, and pharmacy licensure for every state you serve. Launch where you are clearly compliant and expand deliberately.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>5. Write marketing guardrails.<\/strong> No approval claims, no unsubstantiated outcome claims, no research-use-only language. Have counsel review ads, landing pages, and patient emails.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>6. Build an adverse event process.<\/strong> Know who reports to MedWatch and the states, how patients are told how to report, and how complaints are logged and escalated.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>7. Track the rulemaking.<\/strong> The policy is a draft with a Nov 13 comment deadline, and the bulks-list rulemaking is still ahead. Assign someone to monitor changes and update protocols quickly.&nbsp;<\/p>\n\n\n\n<h2 id=\"where-a-white-label-telehealth-platform-fits\" class=\"wp-block-heading\"><strong>Where a white-label telehealth platform fits&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The hard part of a peptide business is not the idea. It is stitching together technology, licensed clinicians, a compliant pharmacy, and lab support, then keeping all of them aligned as the rules move. That is the problem a <a href=\"https:\/\/homelymd.com\/white-label-telehealth-platform\"><strong>white-label telehealth platform<\/strong><\/a> <strong><\/strong>solves.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Homely MD is a white-label telehealth platform built for businesses that want to <a href=\"https:\/\/homelymd.com\/brands\"><strong>start a telehealth business<\/strong><\/a> <strong><\/strong>under their own brand without building the infrastructure themselves. You keep the brand, the patient relationships, and the patient data. Behind it, one contract and one invoice cover four layers:&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Platform:<\/strong> patient portal, dynamic intake, scheduling, charting, e-prescribing, and video, audio, and chat.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Providers:<\/strong> licensed clinicians across all 50 states, with malpractice coverage carried by Homely MD.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Pharmacy:<\/strong> 24+ 503A compounding pharmacy partners with patient-specific compounding and direct-to-patient delivery.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <strong>Labs:<\/strong> five ready-built panels, including Peptide and BPC panels, ordered and resulted in the same chart.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Launch timelines can be as short as seven days, subject to onboarding and approvals. Peptide therapy is one of eight service lines, with no additional per-service-line charge. Which peptides, routes, and states are available at launch depends on pharmacy partner capabilities and the conditions above, so confirm those details during onboarding.<\/p>\n\n\n\n<h2 id=\"ready-to-build-your-telehealth-peptide-program\" class=\"wp-block-heading\"><strong>Ready to build your telehealth peptide program?&nbsp;<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 <a href=\"https:\/\/homelymd.com\/contact\">Talk to Homely MD about launching a branded program<\/a> with the platform, providers, pharmacy network, and labs under one contract.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Visit homelymd.com to get started.<\/p>\n\n\n\n<h3 id=\"frequently-asked-questions\" class=\"wp-block-heading\"><strong>Frequently asked questions&nbsp;<\/strong><\/h3>\n\n\n\n<h4 id=\"is-the-fd-as-interim-access-policy-for-peptides-a-law\" class=\"wp-block-heading\"><strong>Is the FDA&#8217;s interim access policy for peptides a law?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">No. It is a statement of enforcement discretion, issued by HHS as a draft. It does not change the Federal Food, Drug, and Cosmetic Act, does not bind HHS or the public, does not establish rights, and can be amended or withdrawn. It stays in effect until each peptide is addressed in a final rule on the 503A bulks list.&nbsp;<\/p>\n\n\n\n<h4 id=\"are-peptides-now-fda-approved-or-fully-legal-to-sell\" class=\"wp-block-heading\"><strong>Are peptides now FDA-approved or fully legal to sell?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">No. The six covered peptides remain unapproved drugs. The policy means HHS does not intend to act against qualifying 503A compounders who meet all ten conditions. It does not make the peptides approved, safe, or proven effective.&nbsp;<\/p>\n\n\n\n<h4 id=\"which-peptides-does-the-policy-cover\" class=\"wp-block-heading\"><strong>Which peptides does the policy cover?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, each only in the forms and routes listed in the policy&#8217;s appendix. Other peptides, including CJC-1295, ipamorelin, AOD-9604, and emideltide, are not covered.&nbsp;<\/p>\n\n\n\n<h4 id=\"how-do-i-offer-peptides-through-telehealth\" class=\"wp-block-heading\"><strong>How do I offer peptides through telehealth?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Use licensed prescribers who evaluate each patient, send patient-specific prescriptions to a 503A pharmacy that meets the ten conditions, follow the licensure and telehealth rules in each state you serve, and market the products accurately. A white-label telehealth platform can bundle the technology, providers, pharmacy, and labs.&nbsp;<\/p>\n\n\n\n<h4 id=\"do-i-need-a-503-a-compounding-pharmacy-partner\" class=\"wp-block-heading\"><strong>Do I need a 503A compounding pharmacy partner?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. The policy covers state-licensed pharmacies, federal facilities, and licensed physicians compounding under section 503A, and it requires a valid patient-specific prescription. Choose a peptide compounding pharmacy partner that can document each condition.&nbsp;<\/p>\n\n\n\n<h4 id=\"does-the-policy-cover-peptide-blends-or-stacks\" class=\"wp-block-heading\"><strong>Does the policy cover peptide blends or stacks?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">No. The product must contain a single active ingredient from the approved list, so common multi-peptide blends fall outside the policy&#8217;s protection.&nbsp;<\/p>\n\n\n\n<h4 id=\"how-do-i-start-a-telehealth-peptide-business\" class=\"wp-block-heading\"><strong>How do I start a telehealth peptide business?&nbsp;<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Choose your model (new brand, clinic add-on, or audience-led brand), select a compliant 503A pharmacy, set clinical protocols, confirm state compliance, write marketing guardrails, and build an adverse event process. Many founders use a white-label platform to launch faster without building technology or recruiting providers.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For the last three years, building a telehealth peptide program meant operating in a gray zone. Many of the most requested peptides sat on the FDA&#8217;s &#8220;do not compound&#8221; list, and demand moved to gray-market &#8220;research use only&#8221; vials instead. On October 28, 2026, that changed. The federal government released an interim policy that gives [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1856,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[123,104,122],"class_list":["post-1854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-503a-pharmacy-peptides-compliance","tag-start-a-telehealth-peptide-business","tag-telehealth-peptide-program"],"_links":{"self":[{"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/posts\/1854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/comments?post=1854"}],"version-history":[{"count":2,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/posts\/1854\/revisions"}],"predecessor-version":[{"id":1857,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/posts\/1854\/revisions\/1857"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/media\/1856"}],"wp:attachment":[{"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/media?parent=1854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/categories?post=1854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/homelymd.com\/blogs\/wp-json\/wp\/v2\/tags?post=1854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}